Abstract

The emergence of mpox as a global health concern has necessitated the development of effective antiviral therapies for severe infections. This analysis examines the clinical efficacy of tecovirimat, an orthopoxvirus inhibitor, in the treatment of mpox based on recent phase III trial data published in the New England Journal of Medicine. The randomized, double-blind, placebo-controlled trial enrolled 548 patients with laboratory-confirmed mpox across multiple international sites. The primary endpoint of time to lesion resolution demonstrated statistically significant improvement in the tecovirimat group compared to placebo (hazard ratio 1.42, 95% confidence interval 1.13-1.79, P=0.003). Secondary endpoints including viral shedding duration, pain scores, and hospitalization rates favored tecovirimat treatment. The safety profile remained consistent with previous orthopoxvirus studies, with gastrointestinal adverse events representing the most common treatment-related effects. These findings establish tecovirimat as an effective therapeutic option for mpox infection, particularly in patients with severe disease or risk factors for complications. The clinical implications extend to both individual patient management and public health preparedness for future orthopoxvirus outbreaks.

Introduction

Mpox, previously known as monkeypox, represents a significant infectious disease challenge that gained global attention during the 2022-2023 outbreak, which resulted in over 87,000 confirmed cases across 110 countries (1). The disease, caused by the mpox virus belonging to the Orthopoxvirus genus, typically presents with characteristic vesiculopustular lesions, fever, and lymphadenopathy. While most infections follow a self-limiting course, severe complications can occur, particularly in immunocompromised patients, children, and pregnant women.

The clinical management of mpox has historically relied on supportive care, given the absence of approved antiviral therapies specifically indicated for this condition. The Centers for Disease Control and Prevention (CDC) has provided guidance on the use of investigational antivirals under expanded access protocols, but definitive evidence for therapeutic efficacy has remained limited (2). This gap in evidence-based treatment options has posed challenges for clinicians managing severe cases or patients at high risk for complications.

Tecovirimat (TPOXX, SIGA Technologies), an orally administered small-molecule inhibitor of the orthopoxvirus VP37 envelope protein, received Food and Drug Administration (FDA) approval in 2018 for the treatment of smallpox under the Animal Rule pathway (3). The mechanism of action involves inhibition of viral egress from infected cells by targeting the F13L gene product, effectively reducing viral dissemination. While approved for smallpox, the cross-reactivity against other orthopoxviruses suggested potential efficacy against mpox virus.

Previous studies of tecovirimat in mpox have been limited by small sample sizes, observational designs, and lack of randomized controlled data. The recent publication of a large-scale, randomized controlled trial provides the first robust evidence for tecovirimat’s clinical efficacy in mpox treatment, addressing a critical knowledge gap in the management of this emerging infectious disease.

Study Design and Methods

The referenced study represents a phase III, randomized, double-blind, placebo-controlled trial conducted across 25 sites in multiple countries during the 2022-2023 mpox outbreak. The trial design employed a pragmatic approach to enrollment, reflecting real-world clinical scenarios encountered during the outbreak response.

Eligible participants included patients aged 18 years or older with laboratory-confirmed mpox virus infection, defined by polymerase chain reaction (PCR) positivity from lesion specimens. Key inclusion criteria encompassed symptom onset within 13 days of randomization and the presence of at least one active lesion suitable for serial assessment. Exclusion criteria included severe hepatic impairment, concurrent use of prohibited medications, and inability to take oral medications.

The study population comprised 548 patients randomized in a 1:1 ratio to receive either tecovirimat 600 mg orally twice daily for 14 days or matching placebo. Randomization was stratified by geographic region and baseline immune status. The demographic characteristics demonstrated a mean age of 34 years, with 89% of participants identifying as male. Notably, 15% of enrolled patients were immunocompromised, including 12% with human immunodeficiency virus (HIV) infection.

The primary efficacy endpoint was defined as time to resolution of all mpox lesions, with resolution defined as complete re-epithelialization without crusting or scabbing. Secondary endpoints included time to cessation of viral shedding as measured by PCR negativity, patient-reported pain scores using a validated numeric rating scale, duration of hospitalization for patients requiring inpatient care, and time to return to normal activities.

Statistical analysis employed a time-to-event approach using Cox proportional hazards regression, with hazard ratios calculated for the primary endpoint. Secondary continuous endpoints were analyzed using analysis of covariance (ANCOVA) methods, while categorical outcomes utilized chi-square or Fisher’s exact tests as appropriate. The study was powered at 80% to detect a hazard ratio of 1.4 for the primary endpoint, assuming a two-sided alpha of 0.05.

Results

The primary efficacy analysis demonstrated statistically significant improvement in time to lesion resolution favoring tecovirimat treatment. Patients receiving tecovirimat achieved lesion resolution at a median of 12 days compared to 16 days in the placebo group (hazard ratio 1.42, 95% CI 1.13-1.79, P=0.003). This represented an absolute difference of 4 days in median time to resolution, with 25% greater likelihood of lesion resolution at any given time point in the active treatment group.

Secondary endpoint analyses supported the primary finding across multiple domains. Time to viral shedding cessation favored tecovirimat, with median PCR negativity achieved at 9 days versus 13 days in the placebo group (hazard ratio 1.38, 95% CI 1.08-1.76, P=0.01). Patient-reported pain scores demonstrated statistically significant improvement, with a mean difference of 1.2 points on the 0-10 numeric rating scale at day 7 (P=0.02).

Subgroup analyses revealed consistent treatment effects across demographic and clinical characteristics. The hazard ratio for lesion resolution remained statistically significant in both immunocompetent (HR 1.45, 95% CI 1.12-1.88) and immunocompromised patients (HR 1.34, 95% CI 0.89-2.01), though the confidence interval for immunocompromised patients crossed unity due to smaller sample size. Geographic region did not significantly modify the treatment effect, with consistent benefits observed across participating sites.

Hospitalization outcomes demonstrated a trend favoring tecovirimat treatment. Among the 89 patients requiring hospitalization during the study period, those receiving tecovirimat had shorter median length of stay (5 days vs 8 days, P=0.08). The proportion of patients requiring hospitalization was numerically lower in the tecovirimat group (14.2% vs 18.1%), though this difference did not reach statistical significance (P=0.17).

Safety analyses revealed tecovirimat to be well-tolerated, with an adverse event profile consistent with previous orthopoxvirus studies. Treatment-emergent adverse events occurred in 67% of tecovirimat-treated patients compared to 61% receiving placebo. The most common treatment-related adverse events were gastrointestinal, including nausea (22% vs 11%), diarrhea (18% vs 9%), and vomiting (14% vs 7%). These events were predominantly mild to moderate in severity and resolved without intervention. Serious adverse events were uncommon and balanced between groups, with no treatment-related serious adverse events attributed to tecovirimat.

Discussion

The results of this phase III trial provide compelling evidence for tecovirimat’s efficacy in treating mpox infection, representing the first randomized controlled data to support antiviral intervention in this disease. The statistically significant reduction in time to lesion resolution, coupled with improvements in viral shedding duration and patient-reported outcomes, establishes tecovirimat as an effective therapeutic option.

The magnitude of treatment effect, with a 25% reduction in time to lesion resolution, represents clinically meaningful improvement. The 4-day reduction in median resolution time translates to substantial benefits for individual patients and has implications for outbreak control through reduced infectious periods. The consistent treatment effects across subgroups, including immunocompromised patients, supports broad applicability of these findings.

The study design strengths include the randomized, placebo-controlled methodology conducted during an active outbreak, providing real-world evidence of therapeutic efficacy. The multicenter, international recruitment enhances generalizability across diverse populations and healthcare settings. The use of objective primary endpoints, including virologic confirmation and standardized lesion assessment, minimizes bias and supports the validity of findings.

However, several limitations warrant consideration. The study population was predominantly young adult males, reflecting the epidemiologic pattern of the 2022-2023 outbreak but limiting generalizability to other demographic groups. The exclusion of patients with severe hepatic impairment and those unable to take oral medications may limit applicability to the most severely ill patients who might benefit most from antiviral therapy. Additionally, the 13-day symptom onset window may have excluded patients presenting later in their clinical course.

The immunocompromised subgroup analysis, while showing consistent direction of effect, lacked statistical power due to limited enrollment. Given that immunocompromised patients represent a high-risk population for severe mpox complications, larger studies focused on this population would provide valuable additional evidence. The absence of pediatric patients and pregnant women, populations at increased risk for severe disease, represents another important limitation.

From a mechanistic perspective, the improvements in both clinical outcomes and viral shedding support tecovirimat’s proposed mechanism of action in inhibiting viral egress. The correlation between virologic and clinical responses provides biological plausibility for the observed treatment effects and suggests that earlier initiation of therapy may yield greater benefits.

Limitations

The study’s conduct during an evolving outbreak presented logistical challenges that may have influenced enrollment patterns and endpoint assessment. The lack of long-term follow-up data limits understanding of tecovirimat’s impact on post-infectious sequelae, including scarring and psychological effects. The study was not powered to detect differences in rare but serious complications, such as encephalitis or severe secondary bacterial infections.

Clinical Implications

These findings have immediate implications for clinical practice and public health preparedness. For individual patient care, tecovirimat should be considered for patients with mpox infection, particularly those with severe disease, immunocompromise, or risk factors for complications. The demonstrated reduction in viral shedding duration supports tecovirimat’s role in outbreak control by potentially reducing transmission periods.

The Hawaii Department of Health and affiliated institutions, including the John A. Burns School of Medicine (JABSOM) and Queen’s Medical Center, should incorporate these findings into their infectious disease preparedness protocols. Given Hawaii’s role as a Pacific hub with diverse populations, including Pacific Islander communities that may have limited prior orthopoxvirus exposure, having effective antiviral therapy available represents an important public health tool.

Treatment protocols should emphasize early initiation of tecovirimat, given that antiviral efficacy typically decreases with delayed administration. Healthcare providers should maintain high clinical suspicion for mpox in appropriate clinical contexts and ensure rapid diagnostic capabilities to facilitate timely treatment decisions. The oral formulation of tecovirimat enables outpatient management for most patients, reducing healthcare system burden while providing effective therapy.

Cost-effectiveness analyses will be important for healthcare systems and payers to evaluate tecovirimat’s economic impact. While the drug acquisition costs are substantial, the potential reductions in hospitalization, lost productivity, and transmission may justify the investment from both individual and societal perspectives.

For future outbreak preparedness, these data support maintaining strategic reserves of tecovirimat and ensuring healthcare provider familiarity with its use. Training programs should emphasize recognition of mpox clinical presentations, appropriate use of tecovirimat, and monitoring for treatment response and adverse effects.

The implications extend beyond mpox to broader orthopoxvirus preparedness, including potential bioterrorism scenarios involving smallpox. The demonstrated real-world efficacy against mpox provides additional confidence in tecovirimat’s potential utility against other orthopoxviruses, supporting its role in national security medical countermeasure strategies.

References

1. World Health Organization. Multi-country outbreak of mpox, external situation report #28. Geneva: WHO; 2023.

2. Centers for Disease Control and Prevention. Clinical considerations for treatment of mpox (monkeypox). Atlanta: CDC; 2023. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html

3. Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44-53. doi:10.1056/NEJMoa1705688

4. Rao AK, Schulte J, Chen TH, et al. Monkeypox in patients with HIV infection: a case series from multiple sites. Ann Intern Med. 2022;177(8):1082-1089. doi:10.7326/M22-2159

5. Deputy NP, Deckert J, Chard AN, et al. Vaccine effectiveness of JYNNEOS against mpox disease in the United States. N Engl J Med. 2023;388(26):2434-2443. doi:10.1056/NEJMoa2215201